ClinicalTrials.gg
Status unknownNCT04201808Updated Nov 17, 2020

Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

A Phase 4 interventional study of Tenofovir Alafenamide 25 MG in Hepatitis B, Chronic, sponsored by New Discovery LLC. Status unknown at 10 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-17.

Sponsored by New Discovery LLC · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic — 5 open to participants now, 10 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B, Chronic.

Planned enrollment
16th of 26
100 · median 124
Started
2021
with 6 others
Phase 4
14 of 26
4 open now
Registered
12th of 26
by date

Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, this one is the 16th largest by planned enrollment, is one of 7 that started in 2021, is one of 14 in phase 4, and was the 12th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

5 of the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

Both tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are potent antiviral agents for hepatitis B virus (HBV) and recommended by the American Association for the Study of Liver Disease (AASLD) as well as the European Association for the Study of Liver (EASL) guidelines for the treatment of nucleos(t)ide therapy induced HBV resistance. However, it is not clear if chronic hepatitis B (CHB) patients with nucleos(t)ide treatment experience without genotypic mutations would be benefit from TAF therapy. Previous studies have observed that suboptimal response (SOR) following antiviral therapy with nucleos(t)ide treatment is associated with an increased risk of subsequent treatment failure and viral resistance. It remains unclear whether switching to TAF is a reasonable approach in patients with SOR to second-line antivirals Lamivudine (LAM)/ Telbivudine (LdT)/ Adefovir Dipivoxil (ADV) and its combinations with other second-line antivirals for 24 weeks, or SOR to the first-line antiviral Entecavir (ETV) or any antiviral combinations containing ETV for 48 weeks. This study is aimed to determine how the aforementioned patients with SOR to nucleos(t)ide treatment respond to TAF monotherapy. The investigator's study will provide evidence base for therapy selection in SOR patients, especially in China where the majority of patients with CHB are treated with nucleos(t)ide therapy.

Read the detailed description

This is a prospective, single-arm, multicenter cohort study evaluating the efficacy, safety, and tolerability of TAF monotherapy in in Asian CHB adults with SOR to the nucleos(t)ide therapy by assessing the HBV DNA suppression in 48 weeks. Approximately one hundred adults who received the aforementioned nucleos(t)ide therapy will be prospectively enrolled during the period from December 2019 to June 2021. Subjects will be enrolled by medical clinic in about 10 university centers in different regions in China. Approximately 10-15 consecutive eligible patients will be enrolled from each participating sites. This study will be conducted in accordance with the guidelines of Good Clinical Practices (GCPs) including Institutional Review Board (IRB) approval and consent will be applied. Patient identification (ID) will be de-identified for submitting to the central database for analyses from all study sites. Free TAF treatment will be provided to all enrolled patients for 48 weeks. Patients will be under the local standard of care upon the completion of the current study.

Patients aged 18-80 with CHB infection who had received nucleos(t)ide therapy over 24 weeks of LAM/LdT/ADV or 48 weeks of ETV with medication adherence, but failure to achieve the levels of HBV-DNA below 300 IU/mL will be eligible. Subjects will be excluded if they meet the following criteria: co-infected with HIV or other viral hepatitis; the serum levels of HBV DNA are too low (i.e. about 300 IU/mL) to be analyzed for the genotypic mutation(s); nucleos(t)ide resistant mutants have been detected at screening visit, patient is under a clinical research protocol of phase I-III development; unable to consent or unlikely to complete one year follow up after the enrollment; and other medical condition may affect the ability to participate the study.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be 18-80 years of age.
  • Patients must have documented compensated and stable chronic defined by all of the following:

    • HBsAg persistently positive > 6 months.
    • Clinical history, physical findings, and test results are compatible with compensated chronic hepatitis B
  • Patients must have received nucleos(t)ide therapy consisting of LAM/LdT/ADV and its combinations with other antivirals for 24 weeks, or with the first-line antiviral ETV or any antiviral combinations containing ETV for 48 weeks with medication adherence.
  • Although having undergone therapy, patients have had failure to achieve the levels of HBV-DNA below 300 IU/mL.
  • Patient is willing and able to comply with the study drug regimen and all other study requirements.
  • Patient must understand the risk, and be willing and able to provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women, and women who are breastfeeding or who believe they may wish to become pregnant during the course of the study.
  • Males and females of who are not willing to use an effective method of during the study. For males, condoms should be used and for females, a barrier contraception method should be used in combination with one other form of contraception.
  • Unwilling and/or unable to provide written
  • Patients with CHB but are also co-infected with or other viral hepatitis
  • Patients whose serum levels of are too low (i.e. about 300 IU/mL) to be analyzed for the genotypic mutation(s) at the onset of this trial, i.e. baseline
  • At the screening visit, nucleos(t)ide resistant mutants have been detected in the strain of HBV of the patient
  • The patient is under a clinical research protocol of phase I-III development; unable to consent or unlikely to complete one year follow up after the enrollment; and other medical condition may affect the ability to participate the study.
  • Decompensated liver disease defined as direct (conjugated) ≥ 1.2 (ULN); (PT) ≥ 1.2 ULN, ≤ 150,000/mm3, or serum albumin ≤ 3.5 g/dL
  • Prior history of clinical hepatic decompensation (e.g., ascites, jaundice, encephalopathy) or variceal hemorrhage
  • Serum α-fetoprotein ≥ 50 ng/mL
  • Evidence of hepatocellular carcinoma (HCC)
  • History of significant renal disease (e.g., nephrotic syndrome, renal dysgenesis, polycystic kidney disease, congenital nephrosis, acute tubular necrosis, other renal disease)
  • History of significant bone disease (e.g., osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochondrosis, multiple bone fractures)
  • Significant cardiovascular, pulmonary or neurological disease
  • Evidence of a gastrointestinal malabsorption syndrome that may interfere with absorption of orally administered medications
  • History of solid organ or bone marrow transplantation
  • Ongoing therapy with any of the following: Nephrotoxic agents

    • Parenteral aminoglycoside antibiotics (e.g., gentamicin, tobramycin, amikacin)
    • Cidofovir
    • Cisplatin
    • Foscarnet
    • IV amphotericin B
    • IV pentamidine
    • Oral or IV ganciclovir
    • Cyclosporine
    • Tacrolimus
    • IV vancomycin
    • Chronic daily non-steroidal anti-inflammatory drug therapy
    • Competitors of renal excretion (e.g., probenecid) Systemic chemotherapeutic agents
    • Systemic
    • Interleukin-2 (IL-2) and other immunomodulating agents
  • agents (except with the expressed approval of the lead investigators)

Note: administration of any of the above medications must be discontinued at least 30 days prior to the Baseline Visit and for the duration of the study period.

  • Known to the study drugs, the metabolites or formulation
  • Any other condition (including alcohol or substance abuse) or prior therapy that, in the opinion of the Investigators, would make the subject unsuitable for the study or unable to comply with dosing requirements
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Single Arm Intervention Group

    All approximately 100 patients experienced previous suboptimal response to other direct acting antivirals. Patients must have received nucleos(t)ide therapy consisting of LAM/LdT/ADV and its combinations with other second-line antivirals for 24 weeks, or with the first-line antiviral ETV or any antiviral combinations containing ETV for 48 weeks with medication adherence. All patients in this study are in the same arm.

    Drug: Tenofovir Alafenamide 25 MG

Interventions

  • All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.

    Also known as: Vemlidy

06

What researchers measure

Primary outcomes

  1. this study seeks to evaluate the efficacy of TAF in Asian CHB adults with a proven SOR to previous nucleo(t)side therapy by assessing the percentage of patients who achieve HBV DNA viral suppression over a time span of 48 weeks.

    In this study, HBV DNA viral suppression is defined as a HBV DNA level \<20 IU/mL, and previous nucleo(t)side therapy is defined as treatments including LAM, LdT, ADV, and ETV before switching to TAF. The parameters for SOR will be set as patients who exhibit a 1 log10 IU/mL decrease in HBV DNA with medication adherence, but still present with an HBV DNA level of \>300 IU/mL and has no detectable genotype mutation(s) when treated with the second-line antivirals LAM/LdT/ADV and its combinations with other second-line antivirals for 24 weeks, or treated with the first-line antiviral ETV or any antiviral combinations containing ETV for 48 weeks.

    Time frame: 48 weeks

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events in Patients as stratified by the CTCAE v 5.0

    Assess the percentage of Asian CHB adults with SOR to nucleos(t)ide therapy who have adverse events during the study, graded by the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

    Time frame: At 12, 24, 36, and 48 weeks

  2. Percentage of Patients Who Discontinue the Therapy Due to Issues with Tolerability

    To evaluate the frequency of treatment discontinuation in patients who can not tolerate TAF therapy

    Time frame: At 12, 24, 36, and 48 weeks

  3. Percentage of patients with Alanine transferase (ALT) levels within the normal limit

    To calculate the percentage of patients at the end of 48 weeks whose ALT (U/L) levels stay within the normal limit in response to TAF therapy in Asian adults with CHB infection who are SOR to nucleos(t)ide therapy.

    Time frame: 48 weeks

  4. Percentage of patients with Aspartamine transferase (AST) levels within the normal limit

    To calculate the percentage of patients at the end of 48 weeks whose AST (U/L) levels stay within the normal limit in response to TAF therapy in Asian adults with CHB infection who are SOR to nucleos(t)ide therapy.

    Time frame: 48 weeks

  5. Percentage of patients who experience loss/seroconversion of HBsAg and/or HBeAg during the study.

    Assess the percentage of patients who loss/seroconversion of HBsAg or/and HBeAg during the study. Loss is defined by a test showing a negative HBsAg/HBeAg result at the end of the trial, given a positive respective test result at baseline. A seroconversion is defined as a test showing a negative HBsAg and a positive HBsAb result, or a negative HBeAg and a positive HBeAb result at the end of the trial, given a positive HBsAg/HBeAg test result at baseline.

    Time frame: 48 weeks

  6. Percentage of patients with detectable drug resistance mutations

    To evaluate the incidence of drug resistance and drug resistance mutations in 48 weeks of TAF treatment if patients have HBV DNA levels \>300 IU/mL. Drug resistance by population sequencing and genotyping will be done for these patients.

    Time frame: 48 weeks

  7. Percentage of patients who have skipped TAF treatment during the study

    Assess the medication compliance on patients and compare the two sub-groups of patients who will be stratified by the levels of HBV DNA using the cut of of 20 IU/mL at 48 weeks.

    Time frame: 48 weeks.

07

Study locations

10 of 10 sites recruiting
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233000, China
    Recruiting
    • Wei Li, MD · Contactliwei79722.student@sina.com · (+86) 13955292316
    • Shousong' Zhao, MD · Contact1260345655@qq.com · (+86) 13955215571
    • Shousong Zhao, MD · Principal investigator
    • Chuanmiao Liu, MD · Sub investigator
  • Beijing Ditan Hospital, Capital Medical University
    Beijing, Beijing 100015, China
    Recruiting
    • Qi Wang, MD · ContactWangqidl04@126.com · (+86) 15611265361
    • Wen Xie, MD · ContactXiewen6218@163.com · (+86) 13651113763
    • Wen Xie, MD · Principal investigator
    • Ting Zhang, MD · Sub investigator
  • Southwest Hospital
    Chongqing, Chongqing 400038, China
    Recruiting
    • Yuming Wang, MD · Contactwym417@163.com · (+86) 023-65334998
    • Hongfei Huang, MD · Contacthuanghongfei1987@126.com · (+86) 13983068253
    • Yuming Wang, MD · Principal investigator
    • Junnan Li, MD · Sub investigator
  • Liver Research Center, The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian, China
    Recruiting
    • Su Lin, MD · Contactsumer5129@fjmu.edu.cn · (+86) 13809505042
    • Yueyong Zhu, MD · Contactzhuyueyong@fjmu.edu.cn · (+86) 13950233535
    • Yueyong Zhu, MD · Principal investigator
    • Jiaji Jiang, MD · Sub investigator
  • Third Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510630, China
    Recruiting
    • Bixin Xu, MD · Contact718366615@qq.com · (+86) 13622286803
    • Zhiliang Gao, MD · Contactgaozl@21cn.com · (+86) 18922102588
    • Zhiliang Gao, MD · Principal investigator
    • Yubao Zheng, MD · Sub investigator
  • Wuhan Union Hospital, Tongji Medical College (TJMC), Huazhong University of Science and Technology (HUST)
    Wuhan, Hubei 430022, China
    Recruiting
    • Wei Li, MD · Contactlsnlw@sina.com · (+86) 13657254656
    • Dongliang Yang, MD · Contactdlyang@hust.edu.cn · (+86) 13971063026
    • Dongliang Yang, MD · Principal investigator
    • Xin Zheng, MD · Sub investigator
  • Shengjing Hospital of China Medical University
    Shengyang, Liaoning 110004, China
    Recruiting
    • Qiuju Sheng, MD · Contactshengqj@sj-hospital.org · (+86) 18940254812
    • Xiaoguang Dou, MD · Contactguang40@163.com · (+86) 18940251121
    • Xiaoguang Dou, MD · Principal investigator
    • Qiuju Sheng, MD · Sub investigator
  • Department of Infectious Diseases, Xi'an Jiaotong University Second Affiliated Hospital
    Xi'an, Shaanxi 710004, China
    Recruiting
    • Le Ma, MD · Contacthappymale@163.com · (+86) 15029554007
    • Shuang-suo Dang, MD · Contactdang212@126.com · (+86) 13992896471
    • Ya-ping Li, MD · Sub investigator
    • Shuang-suo Dang, MD · Principal investigator
  • Huashan Hospital Fudan University
    Jing'an, Shanghai 200040, China
    Recruiting
    • Chen Chen, MD · Contactatheran@163.com · (+86) 13916484390
    • Wenhong Zhang, MD · Contactzhangwenhong@fudan.edu.cn · (+86) 13801844344
    • Wenhong Zhang, MD · Principal investigator
    • Yuxian Huang, MD · Sub investigator
  • The Third Hospital of Hebei Medical University
    Hebei, Shijiazhuang 050035, China
    Recruiting
    • Ru Ji, MD · Contactjiru0803@163.com · (+86) 15511643992
    • Cai-Yan Zhao, MD · Contactzhaocy2015@163.com · (+86) 18533112898
    • Cai-Yan Zhao, MD · Principal investigator
    • Ya-Dong Wang, MD · Sub investigator
08

References and documents

Publications

  • Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Celen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17. PubMed 29756595 ↗
  • Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22. Erratum In: Lancet Gastroenterol Hepatol. 2016 Nov;1(3):e2. doi: 10.1016/S2468-1253(16)30128-5. PubMed 28404092 ↗
  • European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18. PubMed 28427875 ↗
  • Lu L, Yip B, Trinh H, Pan CQ, Han SH, Wong CC, Li J, Chan S, Krishnan G, Wong CC, Nguyen MH. Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir. J Viral Hepat. 2015 Aug;22(8):675-81. doi: 10.1111/jvh.12368. Epub 2014 Nov 24. PubMed 25417914 ↗
  • Pan CQ, Chan S, Trinh H, Yao A, Bae H, Lou L. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. World J Gastroenterol. 2015 May 14;21(18):5524-31. doi: 10.3748/wjg.v21.i18.5524. PubMed 25987775 ↗
  • Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat. 2012 Mar;19(3):213-9. doi: 10.1111/j.1365-2893.2011.01533.x. Epub 2011 Oct 17. PubMed 22329376 ↗
  • Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800. No abstract available. PubMed 29405329 ↗
  • Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther. 2018 Apr;47(8):1181-1200. doi: 10.1111/apt.14577. Epub 2018 Feb 26. PubMed 29479728 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2021; primary completion for Sep 2023, 28 months later.

Of 63 phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2019
First posted
Dec 17, 2019
StartEst.
May 1, 2021
Primary completionEst.
Sep 30, 2023
CompletionEst.
Sep 30, 2023
Last update
Nov 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04201808
Lead sponsor
New Discovery LLC
Collaborators
Beijing Ditan Hospital
Responsible party
Sponsor
First posted
Dec 17, 2019
Start date
May 1, 2021 (estimated)
Primary completion
Sep 30, 2023 (estimated)
Completion
Sep 30, 2023 (estimated)
Last update
Nov 17, 2020

Study contacts

Wen Xie, MD
Contact
Xiewen6218@163.com
(+86) 13651113763
Calvin Q Pan, MD
Contact
Panc01@nyu.edu
(+001) 7188887728
Calvin Q Pan, MD
principal investigator · NYU Langone Health
Wen Xie, MD
study director · Capital Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion